GLP-1 Muscle Loss: What Ozempic and Mounjaro Are Doing to Your Body

The Hidden Cost of GLP-1 Weight Loss

If you're taking Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1 receptor agonist, you've probably been thrilled watching the number on your scale drop. And you should be — these medications are remarkably effective at reducing body weight, improving metabolic markers, and lowering cardiovascular risk.

But here's what your weight-loss doctor probably isn't telling you: a meaningful share of the weight you're losing isn't fat. It's lean mass — muscle, bone, and connective tissue. Across the published literature, roughly 15-40% of total weight lost on calorically-restricted weight loss is lean tissue, depending on baseline composition, protein intake, and resistance training (Jensen et al., JAMA Network Open, 2024). The AAOS 2026 podium presentations described below didn't measure lean mass directly — they tracked the downstream consequences.

What the AAOS 2026 Research Showed

Two studies presented at the March 2026 American Academy of Orthopaedic Surgeons Annual Meeting put hard numbers on the musculoskeletal cost of GLP-1 therapy.

Study 1 — Bone, Gout, and Osteomalacia (Wajahath et al., Michigan State)

Researchers analyzed 146,966 adults with Type 2 diabetes and obesity, comparing 73,483 GLP-1 users to a matched control group over five years. The findings:

Study 2 — Tendon Ruptures (Lawand et al., UTMB)

A second team analyzed 78,590 matched pairs of obese patients (157,180 total). The headline: ~50% higher relative risk of major tendon ruptures — rotator cuff, Achilles tendon, pectoralis major. The qualitative pattern is what worries clinicians: ruptures occurred during low-load activities like reaching forward or lifting light objects, not during sports or gym workouts.

These are not minor statistics. They represent a fundamental shift in how we should think about GLP-1 therapy.

Why Does This Happen?

When you lose weight rapidly — regardless of the mechanism — your body doesn't selectively burn fat. It breaks down whatever tissues it can access for energy. On GLP-1 medications, the suppressed appetite often means patients aren't consuming enough protein to maintain muscle mass, and the reduced mechanical loading on bones (from being lighter) signals the body to reduce bone density. The same dynamics likely affect tendon integrity, though the exact mechanism behind the Lawand findings is still being characterized.

The result: You look thinner, your metabolic markers improve, but structurally, your body is deteriorating.

The Sarcopenia Cascade

Sarcopenia — the progressive loss of muscle mass and function — is particularly dangerous because:

What You Can Do

1. Resistance Training (Non-Negotiable)

The single most important intervention is structured resistance training — not cardio, not walking, but actual strength training 3+ times per week. This signals your body to preserve muscle during caloric deficit.

2. Protein Optimization

Aim for 0.7-1.0 grams of protein per pound of body weight daily. Most GLP-1 patients are falling dramatically short due to reduced appetite. A protein supplement may be necessary.

3. Critical Supplements

4. Get Monitored

This is the most overlooked piece. You need:

The Bottom Line

GLP-1 medications are powerful tools for weight loss and metabolic health. But they're not without cost. The musculoskeletal side effects are real, they're significant, and they're being largely ignored by the prescribing community.

Your weight-loss doctor manages your metabolism. Someone needs to manage what the weight loss is doing to your bones, muscles, joints, and tendons.

That's exactly what MetaOrtho does.

References

Dr. Jay M. Saenz is a board-certified orthopedic surgeon and the founder of MetaOrthopedics. He specializes in musculoskeletal monitoring for patients on GLP-1 weight loss medications.